Kalaris Therapeutics Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Kalaris Therapeutics Inc.
Former names
Allovir, Inc. ViraCyte, Inc.
Ownership
Public
Status
Active
SIC code
2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation
Delaware
Headquarters city
Berkeley Heights
Headquarters state / province
New Jersey
Headquarters country
United States
Fiscal year end
December
Ticker symbol
KLRS
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001754068
EIN
83-1971007

Board of directors

Follow this board

Chief executives

Diana Brainard · Chief Executive Officer
Dates unknown

Director election results

Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

10 of this board's directors also sit on 16 other boards.

Network of Kalaris Therapeutics Inc.'s board connections Nkarta Inc. Nkarta Inc. Scholar Rock Holding Corporation Scholar Rock Holding C... 4D Molecular Therapeutics Inc. 4D Molecular Therapeut... Alumis Inc. Alumis Inc. Cabaletta Bio Inc. Cabaletta Bio Inc. Eos Energy Enterprises Inc. Eos Energy Enterprises... EyePoint Inc. EyePoint Inc. Immuneering Corporation Immuneering Corporatio... Marker Therapeutics Inc. Marker Therapeutics In... Mineralys Therapeutics Inc. Mineralys Therapeutics... Nektar Therapeutics Nektar Therapeutics PepGen Inc. PepGen Inc. Seer Inc. Seer Inc. SpyGlass Pharma Inc. SpyGlass Pharma Inc. Sutro Biopharma Inc. Sutro Biopharma Inc. vTv Therapeutics Inc. vTv Therapeutics Inc. Anthony P. Adamis Anthony P. Adamis David Hallal David Hallal Diana Brainard Diana Brainard Jeffrey S. Bornstein Jeffrey S. Bornstein Juan Vera Juan Vera Laurie Keating Laurie Keating Leone D. Patterson Leone D. Patterson Michael Dybbs Michael Dybbs Shawn Tomasello Shawn Tomasello Srinivas Akkaraju Srinivas Akkaraju Kalaris Therapeutics Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$6,179,975
2 purchases by 1 insider
Sold, last 12 months
$12,869
1 sale by 1 insider
Date Insider Transaction Shares Price Value
May 20, 2026 Srinivas Akkaraju Director, 10% owner Open-market purchase +244,300 $4.83 $1,179,969
May 20, 2026 Srinivas Akkaraju Director, 10% owner Other −66,906 — —
May 20, 2026 Srinivas Akkaraju Director, 10% owner Other +14,937 — —
May 20, 2026 Srinivas Akkaraju Director, 10% owner Other +4,471 — —
Mar 20, 2026 Hagen Brett R Officer (Chief Accounting Officer) Open-market sale −1,915 $6.72 $12,869
Dec 22, 2025 Srinivas Akkaraju Director, 10% owner Grant or award +1,500,000 $10.00 $15,000,000
Dec 18, 2025 Srinivas Akkaraju Director, 10% owner Open-market purchase +479,847 $10.42 $5,000,006
Mar 26, 2025 Hagen Brett R Officer (Chief Accounting Officer) Open-market sale −907 $8.97 $8,136
Mar 18, 2025 Napoleone Ferrara Director Grant or award +504,000 — —
Mar 18, 2025 Samir Chandrakant Patel Director Grant or award +252,000 — —
Mar 18, 2025 Feinsod Matthew Officer (Chief Medical Officer) Grant or award +4,030 — —
Mar 18, 2025 Srinivas Akkaraju Director, 10% owner Grant or award +11,444,503 — —
Mar 18, 2025 Samir Chandrakant Patel Director Grant or award +100,800 — —
Feb 21, 2025 Vikas Sinha Director, Officer (See Remarks), 10% owner Open-market sale −303 $10.08 $3,054
Feb 21, 2025 Hagen Brett R Officer (Chief Accounting Officer) Open-market sale −96 $10.08 $968

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.